Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Amortization of Deferred Charges (2016 - 2021)

Corcept Therapeutics' Amortization of Deferred Charges history spans 5 years, with the latest figure at $508000.0 for Q4 2021.

  • For Q4 2021, Amortization of Deferred Charges rose 4.96% year-over-year to $508000.0; the TTM value through Dec 2021 reached $2.0 million, up 16.53%, while the annual FY2021 figure was $2.0 million, 16.53% up from the prior year.
  • Amortization of Deferred Charges for Q4 2021 was $508000.0 at Corcept Therapeutics, up from $502000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $508000.0 in Q4 2021 and bottomed at $3000.0 in Q3 2017.
  • The 4-year median for Amortization of Deferred Charges is $385000.0 (2020), against an average of $345933.3.
  • The largest annual shift saw Amortization of Deferred Charges plummeted 40.0% in 2017 before it soared 45.78% in 2020.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $3000.0 in 2017, then skyrocketed by 10966.67% to $332000.0 in 2019, then skyrocketed by 45.78% to $484000.0 in 2020, then grew by 4.96% to $508000.0 in 2021.
  • Per Business Quant, the three most recent readings for CORT's Amortization of Deferred Charges are $508000.0 (Q4 2021), $502000.0 (Q3 2021), and $496000.0 (Q2 2021).